about
Clinical Significance of B-type Natriuretic Peptide in Heart FailureSpotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to dateThe "Vampirome": Transcriptome and proteome analysis of the principal and accessory submaxillary glands of the vampire bat Desmodus rotundus, a vector of human rabiesVenom gland transcriptomes of two elapid snakes (Bungarus multicinctus and Naja atra) and evolution of toxin genesDexamethasone stimulates expression of C-type Natriuretic Peptide in chondrocytes.Upregulation of sestrins protect atriums against oxidative damage and fibrosis in human and experimental atrial fibrillation.Effects of Low-Dose Recombinant Human Brain Natriuretic Peptide on Anterior Myocardial Infarction Complicated by Cardiogenic Shock.ANP attenuates inflammatory signaling and Rho pathway of lung endothelial permeability induced by LPS and TNFalpha.Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failureAtrial natriuretic peptide attenuates LPS-induced lung vascular leak: role of PAK1.Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunctionCardiovascular and metabolic effects of natriuretic peptides.Epac/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection.Nitric oxide, C-type natriuretic peptide and cGMP as regulators of endochondral ossification.Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides.Molecular mechanisms of gonadotropin-releasing hormone signaling: integrating cyclic nucleotides into the network.Control of vascular permeability by atrial natriuretic peptide via a GEF-H1-dependent mechanism.Anti-neutral endopeptidase, natriuretic peptides disarrangement, and proteinuria onset in membranous nephropathy.The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure.Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice.Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.Opposite effects of ANP receptors in attenuation of LPS-induced endothelial permeability and lung injury.Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume.C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and -independent pathways.Atrial natriuretic Peptide in young and elderly children with mild gastroenteritis.Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral ureteral obstruction rats.Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice.Perioperative plasma brain natriuretic peptide and cardiotrophin-1 in off-pump coronary artery bypass.
P2860
Q27005797-7E15D4A7-11E4-4DC6-96F1-425E734ACF28Q28070064-6815ACAF-D468-464D-8F86-6A80D35D6869Q28681336-B835225D-6859-432E-9116-520916F75770Q28743425-5FEE3F6F-22E2-4DE1-9F59-98BD26917685Q33264124-14CF60E7-1BC4-499B-80C7-80F7DFE65F78Q33551782-65E29BD7-5496-4072-8C8B-89583E77995AQ33615284-887CDF74-67A5-4C96-9942-7439251C9AE3Q33618498-6D5C568C-3591-452A-B170-26FBF4F32966Q34161199-CAEBB568-E045-4CF1-80C0-7D72D14BA9DEQ34305451-63520165-7145-47CE-A07D-15800E0789DDQ35407690-6C31C7B8-FDEF-429A-BE04-615F49449F79Q35658084-D7AB197F-8766-4B32-B7DE-74C5205A376FQ36382621-519EBFAC-B434-4948-B0B1-9210343842DFQ36840420-33150397-F50C-4284-B9D0-1430E7820CEEQ37177999-477FE784-1F77-4A8D-AAC3-B15FB1F87F40Q37251037-21DC17BE-5564-4BD4-B967-38B729906820Q37326059-E3F1F787-01D7-48BD-803E-FA543FF8AC5FQ37596383-ED7D9E8D-DE43-4C19-A46D-3DABC7F2615EQ38070067-4F7ADA60-46E8-4B00-91C3-7ECA5CA26544Q38105632-C1BEE5A4-B3E0-4C40-999E-9E018CB4DE84Q38620496-9A30F794-8BBB-404E-829F-8A57D3FAE981Q39011741-7D4490C1-D66A-4E10-990F-405CF4C01610Q41078913-331B27C1-CE7B-447D-A829-9123E42A2B56Q42827494-837DDA32-0C7C-4460-9C50-7FE3EFBE6ED7Q42861749-8EE2F745-E286-4350-91D1-F1CE7416441FQ43101265-CC2BDB93-5C2C-465C-88DB-FF92DDE30D7CQ46335588-B8158FBA-2378-4DCE-9FEB-D949769DEF4DQ46981885-820F6F0B-C130-4635-873B-46DB39E7CC41Q49109702-BCDBFFD4-DC1B-4171-86BE-2AD0ADB851D9
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The natriuretic peptides.
@ast
The natriuretic peptides.
@en
type
label
The natriuretic peptides.
@ast
The natriuretic peptides.
@en
prefLabel
The natriuretic peptides.
@ast
The natriuretic peptides.
@en
P1476
The natriuretic peptides
@en
P2093
Gary F Baxter
P2888
P356
10.1007/S00395-004-0457-8
P577
2004-01-23T00:00:00Z